Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan
| Autor: | Hongwei Wang, Jon P. Fryzek, Jyotsna Mehta, Ruben A. Mesa, Sheikh Usman Iqbal |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Health plan Cancer Research medicine.medical_specialty Adolescent Databases Factual Total cost Pharmacy Comorbidity Young Adult Polycythemia vera Myeloproliferative Disorders Health care medicine Humans Child Myelofibrosis Intensive care medicine Aged Retrospective Studies Aged 80 and over Insurance Health business.industry Essential thrombocythemia Health Care Costs Hematology Middle Aged Patient Acceptance of Health Care medicine.disease United States Oncology Health Resources Female business |
| Zdroj: | Leukemia & Lymphoma. 55:2368-2374 |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |